31 Results for "

V804M

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "V804M" in MCE Product Catalog:

17
17 Cited Publications
Cat. No.: HY-112301
CAS No.: 2097132-94-8
Purity:  99.98%
Synonyms: BLU-667
Target:  

RET

Research Areas:  

Cancer

Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-114370
CAS No.: 2152628-33-4
Purity:  99.83%
Synonyms: LOXO-292
Target:  

RET

Research Areas:  

Cancer

Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
loading...
    loading...
Cat. No.: HY-136534
CAS No.: 2414909-94-5
Purity:  98.22%
Target:  

RET

Research Areas:  

Cancer

RET V804M-IN-1 (compound 5) is a wt-RET -selective inhibitors of RETV804M kinase, with an IC50 of 20 nM .
loading...
    loading...
Cat. No.: HY-139590
CAS No.: 2216753-97-6
Purity:  98.31%
Synonyms: BOS-172738; DS-5010
Target:  

RET PDGFR

Research Areas:  

Cancer

Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity .
loading...
    loading...
Cat. No.: HY-E70779
Target:  

RET

Research Areas:  

Cancer

Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804M is a mutant of RET. RET V804M Recombinant Human Active Protein Kinase is a recombinant RET V804M protein that can be used to study RET V804M-related functions .
loading...
    loading...
Cat. No.: HY-146710
CAS No.: 2259657-48-0
Target:  

RET

Research Areas:  

Cancer

RET-IN-16 is a potent and selective RET inhibitor with IC50s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for RET(WT), RET(M918T), RET(V804L), RET(V804M), RET-CCDC6 and RET-KIF5B, respectively. RET-IN-16 has anticancer effects .
loading...
    loading...
Cat. No.: HY-148742
CAS No.: 2414373-42-3
Purity:  97.00%
Target:  

RET

Research Areas:  

Cancer

RET-IN-21 (compound 5) is a selective RET V804M inhibitor with the IC50 of 0.02 μM. RET-IN-21 does not inhibit the wild type isoforms of RET or KDR. RET-IN-21 has antitumor activity .
loading...
    loading...
Cat. No.: HY-151377
CAS No.: 2484919-71-1
Research Areas:  

Cancer

RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research .
loading...
    loading...
Cat. No.: HY-114370R
CAS No.: 2152628-33-4
Synonyms: LOXO-292 (Standard)
Target:  

Reference Standards RET

Research Areas:  

Cancer

Selpercatinib (Standard) is the analytical standard of Selpercatinib. This product is intended for research and analytical applications. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
loading...
    loading...
Cat. No.: HY-153676
CAS No.: 2479961-46-9
Target:  

RET

Research Areas:  

Cancer

RET-IN-23 (compound 17) is a potent and orally active RET inhibitor with IC50 values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively. RET-IN-23 shows anti-tumor activity .
loading...
    loading...
Cat. No.: HY-112301R
CAS No.: 2097132-94-8
Synonyms: BLU-667 (Standard)
Target:  

Reference Standards RET

Research Areas:  

Cancer

Pralsetinib (Standard) is the analytical standard of Pralsetinib. This product is intended for research and analytical applications. Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
loading...
    loading...
Cat. No.: HY-139590A
CAS No.: 2375837-06-0
Synonyms: BOS-172738 hemiadipate; DS-5010 hemiadipate
Target:  

RET PDGFR

Research Areas:  

Cancer

Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib hemiadipate shows exquisite potency for the wild type RET, RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib hemiadipate has potent antitumor activity .
loading...
    loading...
Cat. No.: HY-144029
CAS No.: 2684258-54-4
Target:  

RET

Research Areas:  

Cancer

RET-IN-13 (compound 1), a quinoline compound, is a potent RET inhibitor with IC50s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research .
loading...
    loading...
Cat. No.: HY-144170
CAS No.: 2755843-62-8
Target:  

RET Btk

Research Areas:  

Cancer

RET-IN-14 (compound 49) is a potent RET inhibitor with IC50s of <0.51 nM, 9.3 nM, 1.3 nM, 9.2 nM, 15 nM for RET (WT), RET (G810R), RET (V804M), BTK and BTK (C481S), respectively. RET-IN-14 has the potential for tumors research
loading...
    loading...
Cat. No.: HY-178061
CAS No.: 2598870-24-5
Target:  

ERK RET

Research Areas:  

Cancer

APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
loading...
    loading...
Cat. No.: HY-144030
CAS No.: 2684252-55-7
Target:  

RET

Research Areas:  

Others

RET-IN-12 (compound 2) is a RET inhibitor, with IC50 values of 0.3 nM and 1 nM for RET(WT) and RET(V804M), respectively .
loading...
    loading...
Cat. No.: HY-132193
CAS No.: 2436473-55-9
Target:  

RET

Research Areas:  

Cancer

RET-IN-4 is a potent, selective and orally active RET inhibitor with IC50s of 1.29 nM, 1.97 nM, and 0.99 nM for RET (WT), RET (V804M), and RET (M918T), respectively. RET-IN-4 exhibits better kinases selectivity against JAK2 (IC50 of 4.4 nM) and FLT3 (IC50 of 30.8 nM). RET-IN-4 has anticancer effects .
loading...
    loading...
Cat. No.: HY-170019
CAS No.: 2479961-45-8
Target:  

RET

Research Areas:  

Cancer

RET-IN-28 (Compound 16) is a RET (transmembrane receptor tyrosine protein kinase) inhibitor. RET-IN-28 inhibits the activity of the mutant RET enzyme (RET-V804M), and can be applied to cancer research .
loading...
    loading...
Cat. No.: HY-112950
CAS No.: 2222755-14-6
Target:  

RET

Research Areas:  

Cancer

RET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
loading...
    loading...
Cat. No.: HY-168105
Target:  

RET

Research Areas:  

Cancer

RET-IN-27 (compound 20p) is a potent inhibitor of RET, with IC50s of 3.6 nM, 0.1 nM, 2.1 nM, 0.3 nM for RET WT, RET V804L, RET V804M, RET M918T, respectively. RET-IN-27 plays an important role in cancer research .
loading...
    loading...